Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies [Corrigendum]

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Corrigendum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336131/
https://www.ncbi.nlm.nih.gov/pubmed/30666139
http://dx.doi.org/10.2147/CEOR.S199650

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336131/
https://www.ncbi.nlm.nih.gov/pubmed/30666139
http://dx.doi.org/10.2147/CEOR.S199650

Ejemplares similares